A prognostically relevant miRNA signature for epithelial ovarian cancer
Menée à partir de 179 échantillons tumoraux prélevés sur des patientes atteintes d'un cancer de l'ovaire, puis validée à partir de 715 autres échantillons tumoraux, cette étude évalue la performance d'une signature, basée sur l'expression de 35 micro-ARNs, pour prédire le risque de récidive ou de progression de la maladie
Although only about 30% of women who present with distant metastatic ovarian cancer will survive for 5 years or more, this proportion is considerably better than that for those individuals who present with advanced cervical, colorectal, kidney, or pancreatic cancer.1 This provides rationale for the relevance of identifying prognostic biomarkers for ovarian cancer to predict outcome and improve understanding of the biological basis of chemotherapy resistance and disease progression. A prognostic gene expression signature has been described for high-grade serous carcinoma, the most common form of epithelial ovarian cancer.
The Lancet Oncology , commentaire, 2015